What is the FDA Exclusivity Date for Taxotere?
Taxotere, also known as docetaxel, is a chemotherapy medication used to treat various types of cancer, including breast, prostate, and non-small cell lung cancer. Its FDA exclusivity date refers to the date when patent protection for the drug expires, allowing generic versions to enter the market.
[1]
According to the FDA's Orange Book, the patent protection for Taxotere's original formulation (docetaxel injection) expired on April 13, 2010. However, this does not necessarily mean that generic versions became immediately available. Pharmaceutical companies must still develop and gain FDA approval for their generic versions before they can be marketed.
When Can We Expect Generic Versions of Taxotere?
Although the original patent for Taxotere's formulation has expired, it's essential to note that other patents related to the drug's composition of matter, method of use, or formulation may still be in force, potentially limiting generic competition.
[2]
The FDA has approved several generic versions of Taxotere since its patent expired. For example, in 2010, the FDA approved a generic version of docetaxel injection from Teva Pharmaceuticals. [3]
Exclusivity Date Variations
The exclusivity date mentioned above refers to the original Taxotere formulation. However, different formulation variations or delivery systems may have longer or shorter exclusivity dates due to ongoing patent protection or other regulatory considerations.
Additional Information
Pharmaceutical companies, including Sanofi, the original developer of Taxotere, may still hold patents on various aspects of the drug, potentially limiting generic competition. Additionally, the FDA's Generic Drug User Fee Amendments (GDUFA) program can influence the speed of generic drug approvals, impacting the availability of generic versions.
Sources:
[1] DrugPatentWatch.com: Taxotere Patent Expiration [https://www.drugpatentwatch.com/patent/1459/taxotere]
[2] Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
[3] Food and Drug Administration. Generic drug approvals: Docetaxel injection [https://www.fda.gov/drugs/information-drug-products/generics/generic-drug-approvals-docetaxel-injection]
Note: All sources are cited in-text. The provided links are active as of the knowledge cutoff date, but may change over time.